ArticleThe Journal of infectious diseases2025
Risk Factors Associated With Tuberculosis Infection Among Household Contacts of Patients With Microbiologically Confirmed Pulmonary Tuberculosis in 3 High Tuberculosis Burden Countries.
Article in The Journal of infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Prevalence and determinants of tuberculosis and COVID-19 among patients with presumptive tuberculosis in a Nigerian tertiary hospital.BMC infectious diseases · 2026Article
- Experiences from Ukraine in expanding TB infection diagnosis and treatment, including for drug-resistant TB.IJTLD open · 2026Article
- Prevalence and risk factors of latent tuberculosis infection among household contacts of tuberculosis patients: a cross-sectional study.Frontiers in public health · 2026Article
- Household Clustering of High-Risk Contacts in Smear-Positive TB Patient Families: Evidence for Hotspot Households and Risk Stratification in Rural Eastern Cape.International journal of environmental research and public health · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
Abstract
backgroundAlthough tuberculosis preventive therapy guidelines support testing for tuberculosis infection in household contacts (HHCs), this adds operational complexity and cost and has often been abandoned. To understand utility of testing, we determined prevalence and risk factors for tuberculosis infection and tuberculosis preventive therapy eligibility among HHCs.
methodsIn a cross-sectional study conducted from July 2021 to September 2022 in Lesotho, South Africa, and Tanzania, we enrolled people with microbiologically confirmed pulmonary tuberculosis and their HHCs. HHCs were screened and tested for tuberculosis and tuberculosis infection using Xpert Ultra and QuantiFERON-TB-Gold-Plus, respectively. Generalized linear modelling was used to determine factors associated with tuberculosis infection, using robust standard errors. Tuberculosis preventive therapy eligibility was determined using World Health Organization criteria.
resultsWe enrolled 342 people with pulmonary tuberculosis and 964 HHCs: 61.9% (597/964) were female with a median age of 18 years (interquartile range, 8-39 years). Overall, tuberculosis prevalence was 3.4% (25/739; 95% confidence interval [CI], 2.2%-4.9%), while tuberculosis infection prevalence was 48.7% (348/714; 95% CI, 45.0%-52.5%). Having tuberculosis infection increased with age per year (adjusted odds ratio [aOR], 1.02; 95% CI, 1.01-1.03), being from Lesotho (aOR, 1.82; 95% CI, 1.04-3.20), previous tuberculosis history (aOR, 2.25; 95% CI, 1.05-4.79), and being HIV negative (aOR, 2.30; 95% CI, 1.31-4.04). Overall, 62.2% (518/833; 95% CI, 58.8%-65.5%) were eligible for tuberculosis preventive therapy.
conclusionsAlmost half of tuberculosis-exposed HHCs aged ≥5 years had tuberculosis infection. Approximately two-thirds of HHCs were eligible for tuberculosis preventive therapy, implying that providing tuberculosis preventive therapy without prior testing for tuberculosis infection may be warranted in this population. Further work on cost-effectiveness is warranted when new tests become available. CLINICAL TRIALS REGISTRATION: ISRCTN10003903.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.